Alexey Vadimovich Zilov

Alexey Vadimovich Zilov

Auto-generated profile, based on publicly available information

Alexey Vadimovich Zilov

Sechenov First Moscow State Medical University (Sechenov University)

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 December 2017 in Obesity and metabolism
Verified
Journal Article
Open access
PDF file
IDIvan I. Dedov
Ivan I. Dedov
GMGalina A. Mel'NIchenko
Galina A. Mel'NIchenko
MSMarina Shestakova
Marina Shestakova
RRRoman V. Rozhivanov
Roman V. Rozhivanov
ATAnna L. Terehova
Anna L. Terehova
DKDmitriy G. Kurbatov
Dmitriy G. Kurbatov
Hypogonadism in men, defined as a reduction in serum testosterone in combination with characteristic symptoms and/or signs (described in detail later), is common in diabetes mellitus (DM). These recommendations do not cover the whole range of pathologies that cause the development of testosterone deficiency (hypogonadism), but focus on its clinical variants and characteristic for men with diabetes. The recommendations provide data on the prevalence of hypogonadism in diabetes, its etiology. In the section "diagnostics" the features of anamnesis of patients with hypogonadism with diabetes, the necessary methods of physical and laboratory examination are presented in detail. The risk factors and clinical consequences of hypogonadism are separately examined. In the section "choice of treatment methods", there are possible treatment options for such patients using various androgenic therapies, taking into account the needs of the man, maintaining his reproductive function and risk factors. Particular attention is paid to indications, contraindications and risk factors for androgen therapy in men with diabetes, especially in old age. With this in mind, principles for monitoring the treatment are developed. Based on a large number of studies, favorable effects of androgen replacement therapy in men with hypogonadism and diabetes have been demonstrated.

16 September 2024 in Problems of Endocrinology
Verified
Journal Article
Open access
PDF file
AEA D Erlikh
A D Erlikh
AZA V Zilov
A V Zilov
DSDmitri Shchekochikhin
Dmitri Shchekochikhin
SSS B Shornikov
S B Shornikov
EBE V Bublik
E V Bublik
ERE G Ryzhkova
E G Ryzhkova
The prevalence of cardiovascular diseases (CVDs) is well known. According to the World Health Organization (WHO), almost 18 million people die from CVDs worldwide every year, accounting for 31% of all causes of death [1]. CVDs often develop concomitantly with diabetes mellitus (DM), with approximately 20% of cardiovascular deaths attributed to elevated blood glucose levels [2]. Notably, CVDs are the leading cause of death among patients with type 2 diabetes (T2DM). Based on data from the Federal Register of Diabetes 2022 in Russia, chronic heart failure was the direct cause of death in 24.2% of T2DM cases, followed by acute heart failure (13.1%), cerebrovascular events (10.0%), and myocardial infarction (3.7%) [3].The pathophysiological interplay between atherosclerotic cardiovascular disease and DM has led to a situation where cardiologists are increasingly involved in the treatment of patients with DM, while endocrinologists are encountering a growing number of patients with CVDs. This association has become so apparent that in a recent article published in the European Journal of Cardiology, Yu. Braunwald speculated about the emergence of a new subspecialty - diabetocardiology [4]. Unfortunately, experts predict that the global number of diabetic patients will reach 783 million [5].Recent data on the CV benefits of certain hypoglycemic drugs (primarily, certain SGLT2 inhibitors, several GLP-1 receptor agonists, and a novel non-steroidal mineralocorticoid receptor antagonist finerenone) prove the need for a unified interdisciplinary approach to managing CVDs and DM.Given the importance of integrated and coordinated efforts in managing patients with CVD and DM, the Task Force of the ­European Society of Cardiology (ESC) updated, formulated, and published clinical guidelines on the treatment of CVD in diabetic patients in 2023 [6]. This article provides a concise overview of the key provisions outlined in the guidelines.

20 August 2019 in Diabetes mellitus
Verified
Journal Article
Open access
PDF file
MAMikhail Antsiferov
Mikhail Antsiferov
GGGagik Galstyan
Gagik Galstyan
AZAlexey Zilov
Alexey Zilov
AMAlexander Mayorov
Alexander Mayorov
TMTatyana Markova
Tatyana Markova
AVAlisa Vitebskaya
Alisa Vitebskaya
The Scientific Advisory Board, chaired by Professor G. R. Galstyan (cochair - A.V. Zilov), met in Moscow on 19 June 2018 to discuss the possibilities of improving the results of diabetes mellitus (DM) treatment by considering glycaemic variability (GV) as an additional criterion for effective glycaemic control (especially in patients receiving insulin therapy) and as one of the goals of treatment in patients with unstable glycaemia. The purpose of the working meeting was to develop a strategy for the introduction of GV as a predictor and as an additional criterion for assessing the effectiveness and safety of hypoglycaemic therapy to improve the pharmacotherapy of diabetes and reduce cardiovascular and total mortality. The aims of the working meeting were to conduct a comprehensive data analysis of the relationship between GV and hypoglycaemia; to gather and analyse published data and the experience of decrease in GV and improved outcomes of diabetes against the background of different types of insulin therapy; to compare existing methods of glycaemia monitoring and GV assessment and examine their validity and availability in real practice in the context of limited budget and to analyse the informativeness and clinical and prognostic significance of various parameters of GV assessment and to determine their reasonable minimum for a comprehensive assessment of GV as a criterion for evaluating the effectiveness of DM treatment and the predictors of negative diabetes outcomes. The following reports were presented during the discussion: Glycemic variability: clinical and prognostic value. Types of glycemic variability (Candidate of Medical Sciences, assistant Professor Zilov A.V.); Methods of assessment of variability of glycemia in clinical trials and routine practice (PhD, Professor Markova T. N.); Current international and national recommendations on glycemic monitoring (PhD, Professor Galstyan G. R.) and Peculiarities of glycemic variability and its evaluation among children and adolescents (Candidate of Medical Sciences Vitebskaya A.V.).

1 September 2013 in Diabetes Research and Clinical Practice
Verified
Journal Article
Open access
AZAlexey Zilov
Alexey Zilov
NNNabil El Naggar
Nabil El Naggar
SSSiddharth Shah
Siddharth Shah
CSChunduo Shen
Chunduo Shen
JHJihad Haddad
Jihad Haddad
This subgroup analysis of the A₁chieve study examined data from 15,545 people who started treatment with insulin detemir ± oral glucose-lowering drugs in routine clinical care. A₁chieve was a 24-week, international, prospective, non-interventional study of people with type 2 diabetes from non-Western nations starting treatment with basal insulin detemir, bolus insulin aspart or biphasic insulin aspart 30, alone or in combination, to evaluate their safety and effectiveness in routine clinical practice. HbA₁c for the global cohort improved after 24 weeks from 9.5 ± 1.6% by -2.0 ± 1.6% [80 ± 17 by -22 ± 17 mmol/mol] (-2.1 ± 1.6% [-23 ± 17 mmol/mol] for insulin-naïve participants; -1.6 ± 1.7% [-17 ± 19 mmol/mol] for prior insulin users). Fasting plasma glucose and postprandial plasma glucose were also significantly reduced (p<0.001), irrespective of prior therapy or geographical region. The incidence of major hypoglycaemia decreased significantly over 24 weeks in both the insulin-naïve and insulin-experienced groups (p<0.0001). Mean body weight decreased overall by -0.4 ± 4.0 kg and blood pressure, lipid profiles, and self-reported quality of life improved over 24 weeks for all people starting treatment with insulin detemir. People with type 2 diabetes in poor glycaemic control starting treatment with insulin detemir reported significant improvements in glycaemic control with improved treatment tolerability, irrespective of prior treatment and geographical region, after 24 weeks.

2 June 2021 in Russian Journal of Gastroenterology, Hepatology, Coloproctology
Verified
Journal Article
Open access
PDF file
ABA. O. Bueverov
A. O. Bueverov
AZA. V. Zilov
A. V. Zilov
Aim. An up-to-date review of the prevalence, pathogenesis, diagnosis and management of hepatological complications of type 1 diabetes mellitus (T1D).Key points. Diabetes type 1 causes a markedly more common liver injury than traditionally assumed. Three types of hepatic damage have been described to date in T1D patients, steatosis, glycogen hepatopathy and diabetic hepatosclerosis, with the latter two apparently pathognomonic of this diabetes type. Their pathogenesis is complex and not fully understood. Its important link is a likely inherited non-physiological insulin supply to the tissue, especially at marked glycaemic fluctuations. An adequate glycaemic control is the main prevention and treatment measure in these conditions. The practitioner’s understanding of liver damage in T1D is an earnest to avoid unnecessary tests and ineffective medications.Conclusion. Both endocrinologists and internists ought to contemplate the possibility of liver involvement in T1D for improving the patient outcomes.

24 May 2025 in Meditsinskiy sovet = Medical Council
Verified
Journal Article
Open access
PDF file
AZA. V. Zilov
A. V. Zilov
LBL. Z. Bolieva
L. Z. Bolieva
Introduction. Treatment of type 2 diabetes mellitus (T2DM) and its complications impose a substantial economic burden on the healthcare system. Timely and high-quality follow-up monitoring of patients with prediabetes by primary care physicians helps prevent the development of diabetes mellitus and the progression of complications.Aim. To evaluate the experience of the use of Subetta in real-world clinical practice in patients with prediabetes. https://doi.org/10.21518/ms2025-128Materials and methods. A 3-month Subetta monotherapy was assessed in 1,101 patients with verified prediabetes who had not previously received antidiabetic treatment. The follow-up monitoring period was 12 weeks, during which the patients received Subetta at a dose of 2 tablets twice a day. The primary efficacy endpoints included changes in fasting plasma glucose levels, glycated hemoglobin (HbA1c) levels and OGTT two-hour blood glucose levels as compared with baseline values 3 months after Subetta therapy.Results. The 12-week Subetta therapy showed a significant decrease in all studied carbohydrate metabolism parameters. The average decrease in HbA1c levels among all patients with prediabetes was 0.3% (p < 0.001). Over the follow-up period, OGTT two-hour blood glucose levels decreased by an average of 0.87 mmol/l (p < 0.001). The average fasting glucose level decrease was 0.62 mmol/l (p < 0.001). This therapy had a high safety profile, as only 8 adverse events were recorded in 5 patients (0.5% of cases) during the study.Conclusions. The study demonstrated high efficacy and a favourable safety profile of Subetta in monotherapy of patients with prediabetes. After 3 months of treatment, normoglycemia state based on the OGTT two-hour blood glucose levels was achieved in approximately 70% of patients.